$-0.22 EPS Expected for TherapeuticsMD, Inc. (TXMD)

October 13, 2018 - By Peter Kolinski

TherapeuticsMD, Inc. (NASDAQ:TXMD) LogoInvestors sentiment decreased to 1.24 in 2018 Q2. Its down 0.23, from 1.47 in 2018Q1. It dropped, as 16 investors sold TherapeuticsMD, Inc. shares while 35 reduced holdings. 19 funds opened positions while 44 raised stakes. 156.02 million shares or 2.78% less from 160.49 million shares in 2018Q1 were reported.
State Board Of Administration Of Florida Retirement holds 0% or 74,954 shares. Outfitter Advsr Ltd holds 51,532 shares or 0.15% of its portfolio. Parallax Volatility Advisers Limited Partnership holds 0% or 9,098 shares. Jefferies Gp Limited Liability Corporation reported 0% stake. Ubs Asset Management Americas has invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Bluecrest Capital Mgmt Limited holds 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD) or 17,433 shares. Amalgamated National Bank stated it has 25,780 shares. Berson & Corrado Invest Advisors Ltd Liability Com holds 72,185 shares. Quantitative Mngmt Limited Liability Corp owns 191,200 shares. Moreover, Gagnon Ltd Limited Liability Company has 0.03% invested in TherapeuticsMD, Inc. (NASDAQ:TXMD). Td Asset Management owns 427,602 shares for 0% of their portfolio. Alpine Woods Cap Investors Llc holds 0.02% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 17,000 shares. Bancshares Of Mellon Corporation accumulated 30.46 million shares. 15,700 were reported by Great West Life Assurance Can. State Common Retirement Fund has invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD).

Since August 21, 2018, it had 1 insider purchase, and 3 sales for $3.80 million activity. Thompson Tommy G had bought 4,000 shares worth $22,100 on Tuesday, August 21. $1.52 million worth of TherapeuticsMD, Inc. (NASDAQ:TXMD) was sold by Milligan John C.K. IV. Bernick Brian sold $1.15M worth of stock or 182,800 shares.

Analysts expect TherapeuticsMD, Inc. (NASDAQ:TXMD) to report $-0.22 EPS on November, 5.They anticipate $0.15 EPS change or 214.29 % from last quarter’s $-0.07 EPS. After having $-0.15 EPS previously, TherapeuticsMD, Inc.’s analysts see 46.67 % EPS growth. The stock decreased 3.04% or $0.17 during the last trading session, reaching $5.42. About 3.15 million shares traded or 26.87% up from the average. TherapeuticsMD, Inc. (NASDAQ:TXMD) has declined 1.40% since October 13, 2017 and is downtrending. It has underperformed by 17.02% the S&P500.

TherapeuticsMD, Inc. operates as a women's health care product company. The company has market cap of $1.28 billion. The firm makes and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. It currently has negative earnings. The Company’s pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

TherapeuticsMD, Inc. (NASDAQ:TXMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>